Sign In to Follow Application
View All Documents & Correspondence

Antimicrobial Formulation

Abstract: An antimicrobial formulation comprising in a carrier, biologically stabilized silver nano particles of average size of about 1to 100 nm and concentration in the range of about 1 to 100 ppm in combination with hyaluronic acid having concentration in the range of about 0.05% TO 5%.

Get Free WhatsApp Updates!
Notices, Deadlines & Correspondence

Patent Information

Application #
Filing Date
12 October 2006
Publication Number
30/2008
Publication Type
INA
Invention Field
MICRO BIOLOGY
Status
Email
Parent Application

Applicants

NANO CUTTING EDGE TECHNOLOGY PVT. LTD.,
79/87, D. LAD PATH, KALACHOWKI, MUMBAI 400 033,

Inventors

1. PAKNIKAR KISHORE MADHUKAR
C/O. AGHARKAR RESEARCH INSTITUTE OF MAHARASHTRA FOR THE CULTIVATION OF SCIENCE, G.G.AGARKAR ROAD, PUNE 411 004,
2. JAIN JAYA
C/O. Agharkar Research Institute of Maharashtra for the cultivation of Science, G.G.Agarkar Road, Pune 411 004, Maharashtra, India

Specification

FORM-2 THE PATENTS ACT, 1970 (39 of 1970) & THE PATENTS RULES 2003 Complete Specification (See section 10 and rule 13) ANTIMICROBIAL FORMULATION NANO CUTTING EDGE TECHNOLOGY PVT. LTD. an Indian Company of 79/87, D. Lad Path, Kalachowki, Mumbai 400 033, Maharashtra, India THE FOLLOWING SPECIFICATION PARTICULARLY DESCRIBES THE INVENTION AND THE MANNER IN WHICH IT IS TO BE PERFORMED. FIELD OF INVETION This invention relates to an antimicrobial formulation. BACKGROUND OF INVENTION The usefulness of silver (symbol- Ag, atomic number-47) as an antimicrobial agent has been known for a long time. For thousands of years silver has been used as a healing and anti-bacterial agent by civilizations throughout the world. Its medical, preservative and restorative powers can be traced as far back as the ancient Greek and Roman Empires. Long before the development of modern pharmaceuticals, silver was employed as a germicide and antibiotic: • The Greeks used silver vessels to keep water and other liquids fresh. Herodotus, the Greek philosopher and historian, dates the use of silver to before the birth of Christ. • The Roman Empire stored wine in silver urns to prevent spoilage. • The use of silver is mentioned in ancient Indian and Egyptian writings. • In the Middle Ages, silverware protected the wealthy from the full brunt of the plague. • Before the advent of modern germicides and antibiotics, it was known that disease-causing pathogens could not survive in the presence of silver. Consequently, silver was used in dishware, drinking vessels and eating utensils. • In particular, the wealthy stored and ate their food from silver vessels to keep bacteria from growing. • The Chinese emperors and their courts ate with silver chopsticks. • The Druids have left evidence of their use of silver. • Settlers in the Australian outback suspend silverware in their water tanks to retard spoilage. • Pioneers trekking across the American West found that if they placed silver or copper coins in their casks of drinking water, it kept the water safe from bacteria, algae, etc. • All along the frontier, silver dollars were put in milk to keep it fresh. • Silver leaf was used to combat infection in wounds sustained by troops during World War I. • Prior to the introduction of antibiotics. Colloidal silver was used widely in hospitals and has been known as a bactericide for at least 1200 years. • In the early 1800s. doctors used silver sutures in surgical wounds with very successful results. Not until the late 1800's did eastern scientists re-discover what had been known for thousands of years-that silver is a powerful germ fighter. Medicinal silver compounds were then developed and silver became commonly used as a medicine. By the early part of the 1900s. the use of silver as an antibacterial substance was becoming widespread. By 1940 there were approximately four dozen different silver compounds in the market being used to treat every known infectious disease. These were available in oral, injectable, and topical forms. However, these medicinal silver preparations caused a discoloration of the skin called argyria specially certain types of protein-bound silver compounds and improperly prepared and unstable compositions. New knowledge of body chemistry gave rise to the enormous array of applications for colloidal disinfectants and medicines and for on-going research into the capabilities and possibilities for silver colloids. However, Silver's "new-found" fame as a superior infection-fighting agent was short lived. During the 1930s, synthetically manufactured drugs began to make their appearance and the profits, together with the simplicities of manufacturing this new source of treatment, became a powerful force in the marketplace. There was much excitement over the new 'wonder drugs' and at that time, no antibiotic-resistant strains of disease organisms had surfaced. Silver quickly lost its status to modern antibiotics. The use of some silver preparations in mainstream medicine survived. Among them are the use of dilute silver nitrate in newborn babies' eyes to protect from infection and the use of "Silvadine", a silver based salve, in burn wards to kill infection. Silver based bandages have also been approved by the FDA and licensed for sale. Other uses that did not lose favor include: • Silver water purification filters and tablets are used to prevent growth of algae and bacteria. • Electrical ionization units that impregnate the water with silver and copper ions are used to sanitize pool water without the harsh effects of chlorine. • Silver has been used to sterilize recycled water on space vehicles. • The Swiss use silver filters in homes and offices- • Municipalities use silver in treatment of sewage- • Silver is a popular agent in the fight against airborne toxins as well other industrial poisons. But for the most part, with the discovery of pharmaceutical antibiotics, interest in Silver as an anti-microbial agent declined almost to the point of extinction. Silver re-emerged as an adjunct to antibiotic treatment £S a result of the notable work of Dr. Margraf who found that the use of diluted silver nitrate to a 5 percent solution was found to kill invasive burn bacteria and permitted wounds to heal. Importantly, resistant strains did not appear. Silver nitrate was widely used in 1960s for the treatment of burn victims by Moyer. But, silver nitrate was far from ideal. Eventually, it was not co^i^eced as a

Documents

Orders

Section Controller Decision Date

Application Documents

# Name Date
1 1688-MUM-2006-CLAIMS(AMENDED)-(26-2-2010).pdf 2018-08-09
1 1688-MUM-2006-FORM 2(TITLE PAGE)-(PROVISIONAL)-(12-10-2006).pdf 2006-10-12
2 1688-MUM-2006-CLAIMS(AMENDED)-(9-7-2010).pdf 2018-08-09
2 1688-MUM-2006-FORM 2(PROVISIONAL)-(12-10-2006).pdf 2006-10-12
3 1688-MUM-2006-DESCRIPTION(PROVISIONAL)-(12-10-2006).pdf 2006-10-12
3 1688-MUM-2006-CLAIMS(MARKED COPY)-(26-2-2010).pdf 2018-08-09
4 1688-mum-2006-form 5(12-10-2007).pdf 2007-10-12
4 1688-MUM-2006-CLAIMS(MARKED COPY)-(9-7-2010).pdf 2018-08-09
5 1688-mum-2006-form 2(title page)-(12-10-2007).pdf 2007-10-12
5 1688-mum-2006-correspondence(16-5-2008).pdf 2018-08-09
6 1688-mum-2006-form 2(12-10-2007).pdf 2007-10-12
6 1688-MUM-2006-CORRESPONDENCE(IPO)-(18-3-2011).pdf 2018-08-09
7 1688-mum-2006-correspondence-received.pdf 2018-08-09
8 1688-mum-2006-drawing(12-10-2007).pdf 2007-10-12
8 1688-mum-2006-description (provisional).pdf 2018-08-09
9 1688-mum-2006-description(complete)-(12-10-2007).pdf 2007-10-12
9 1688-mum-2006-form 18(16-5-2008).pdf 2018-08-09
10 1688-mum-2006-claims(12-10-2007).pdf 2007-10-12
10 1688-MUM-2006-FORM 26(26-2-2010).pdf 2018-08-09
11 1688-MUM-2006-FORM 26(30-9-2010).pdf 2018-08-09
12 1688-MUM-2006-ABSTRACT(12-10-2007).pdf 2007-10-12
12 1688-MUM-2006-FORM 26(9-7-2010).pdf 2018-08-09
13 1688-mum-2006-correspondence(ipo)-(24-11-2009).pdf 2009-11-24
13 1688-mum-2006-form-1.pdf 2018-08-09
14 1688-MUM-2006-REPLY TO HEARING(18-11-2010).pdf 2010-11-18
15 1688-mum-2006-form-2.pdf 2018-08-09
15 1688-MUM-2006-OTHER DOCUMENT(18-11-2010).pdf 2010-11-18
16 1688-MUM-2006-CLAIMS(MARKED COPY)-(18-11-2010).pdf 2010-11-18
16 1688-mum-2006-form-26.pdf 2018-08-09
17 1688-mum-2006-form-3.pdf 2018-08-09
17 1688-MUM-2006-CLAIMS(AMENDED)-(18-11-2010).pdf 2010-11-18
18 1688-MUM-2006-REPLY TO EXAMINATION REPORT(26-2-2010).pdf 2018-08-09
18 1688-MUM-2006-CANCELLED PAGES(18-11-2010).pdf 2010-11-18
19 1688-MUM-2006-REPLY TO EXAMINATION REPORT(9-7-2010).pdf 2018-08-09
19 1688-MUM-2006_EXAMREPORT.pdf 2018-08-09
20 1688-MUM-2006-SPECIFICATION(AMENDED)-(26-2-2010).pdf 2018-08-09
21 1688-MUM-2006-REPLY TO EXAMINATION REPORT(9-7-2010).pdf 2018-08-09
21 1688-MUM-2006_EXAMREPORT.pdf 2018-08-09
22 1688-MUM-2006-CANCELLED PAGES(18-11-2010).pdf 2010-11-18
22 1688-MUM-2006-REPLY TO EXAMINATION REPORT(26-2-2010).pdf 2018-08-09
23 1688-MUM-2006-CLAIMS(AMENDED)-(18-11-2010).pdf 2010-11-18
23 1688-mum-2006-form-3.pdf 2018-08-09
24 1688-mum-2006-form-26.pdf 2018-08-09
24 1688-MUM-2006-CLAIMS(MARKED COPY)-(18-11-2010).pdf 2010-11-18
25 1688-mum-2006-form-2.pdf 2018-08-09
25 1688-MUM-2006-OTHER DOCUMENT(18-11-2010).pdf 2010-11-18
26 1688-MUM-2006-REPLY TO HEARING(18-11-2010).pdf 2010-11-18
27 1688-mum-2006-correspondence(ipo)-(24-11-2009).pdf 2009-11-24
27 1688-mum-2006-form-1.pdf 2018-08-09
28 1688-MUM-2006-ABSTRACT(12-10-2007).pdf 2007-10-12
28 1688-MUM-2006-FORM 26(9-7-2010).pdf 2018-08-09
29 1688-MUM-2006-FORM 26(30-9-2010).pdf 2018-08-09
30 1688-mum-2006-claims(12-10-2007).pdf 2007-10-12
30 1688-MUM-2006-FORM 26(26-2-2010).pdf 2018-08-09
31 1688-mum-2006-description(complete)-(12-10-2007).pdf 2007-10-12
31 1688-mum-2006-form 18(16-5-2008).pdf 2018-08-09
32 1688-mum-2006-drawing(12-10-2007).pdf 2007-10-12
32 1688-mum-2006-description (provisional).pdf 2018-08-09
33 1688-mum-2006-correspondence-received.pdf 2018-08-09
34 1688-mum-2006-form 2(12-10-2007).pdf 2007-10-12
34 1688-MUM-2006-CORRESPONDENCE(IPO)-(18-3-2011).pdf 2018-08-09
35 1688-mum-2006-form 2(title page)-(12-10-2007).pdf 2007-10-12
35 1688-mum-2006-correspondence(16-5-2008).pdf 2018-08-09
36 1688-mum-2006-form 5(12-10-2007).pdf 2007-10-12
36 1688-MUM-2006-CLAIMS(MARKED COPY)-(9-7-2010).pdf 2018-08-09
37 1688-MUM-2006-DESCRIPTION(PROVISIONAL)-(12-10-2006).pdf 2006-10-12
37 1688-MUM-2006-CLAIMS(MARKED COPY)-(26-2-2010).pdf 2018-08-09
38 1688-MUM-2006-CLAIMS(AMENDED)-(9-7-2010).pdf 2018-08-09
38 1688-MUM-2006-FORM 2(PROVISIONAL)-(12-10-2006).pdf 2006-10-12
39 1688-MUM-2006-CLAIMS(AMENDED)-(26-2-2010).pdf 2018-08-09
39 1688-MUM-2006-FORM 2(TITLE PAGE)-(PROVISIONAL)-(12-10-2006).pdf 2006-10-12